Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Shuji Shimada"'
Publikováno v:
Journal of Diabetes Research, Vol 2020 (2020)
Background. Several clinical trials have addressed the therapeutic strategy of adding dipeptidyl peptidase 4 (DPP-4) inhibitors to the treatment of type 2 diabetes mellitus (DM) inadequately controlled by insulin therapy. However, there is a high deg
Externí odkaz:
https://doaj.org/article/954f6e6f387c4453b7cbe3fbc0416700
Autor:
AYAKO MAEDA-MINAMI, MAIKO HOSOKAWA, YUMI ISHIKURA, ATSUTO ONODA, YOHEI KAWANO, KENICHI NEGISHI, SHUJI SHIMADA, TOMOMI IHARA, MASAO SUGAMATA, KEN TAKEDA, YASUNARI MANO
Publikováno v:
Anticancer Research. 42:3717-3724
An association between leukotriene receptor antagonists (LTRA) and cancer has been previously reported, but the relationship between LTRA use and cancer prevention remains controversial. This study aimed to clarify the cancer-preventive effect of LTR
Autor:
Yohei Kawano, Yuichiro Yamamoto, Masashi Nagata, Shuji Shimada, Yasunari Mano, Masakazu Yamaguchi, Ayako Maeda-Minami, Kenji Kawasumi, Reiko Matsui, Takao Aoyama, Kenichi Negishi, Azusa Kujirai
Publikováno v:
Anticancer Research. 41:5827-5834
BACKGROUND/AIM Recently, the number of patients with cancer receiving outpatient chemotherapy using oral anticancer drugs has increased, but the currently available outpatient cancer chemotherapy is not safer than that available before. The present s
Autor:
Tatsunori Suzuki, Tomoki Nishikawa, Masashi Nagata, Aya Enomoto, Yuuki Akagi, Takao Aoyama, Mai Hoshiko, Kenichi Negishi, Azusa Kujirai, Shuji Shimada, Saeko Nakamura, Emi Tsukada, Yasunari Mano, Satoshi Nakamatsu, Yohei Kawano
Publikováno v:
Biological and Pharmaceutical Bulletin. 44:611-619
Oral anticoagulants (OACs) pose a major bleeding risk, which may be increased or decreased by concomitant medications. To explore medications that affect the bleeding risk of OACs, we conducted a nested case-control study including 554 bleeding cases
Autor:
Masashi Nagata, Kenichi Negishi, Ayano Mori, Satoshi Nakamatsu, Namiki Sakamoto, Takao Aoyama, Yasunari Mano, Yohei Kawano, Maho Katsuyama, Shuji Shimada, Maki Obana
Publikováno v:
Biological and Pharmaceutical Bulletin. 44:238-244
Mirtazapine (MTZ) is a noradrenergic and specific serotonergic antidepressant. MTZ is reportedly associated with an increased risk of bleeding. However, the underlying mechanism remains unclear. In this study, we investigated the antiplatelet effect
Publikováno v:
Journal of Diabetes Research
Journal of Diabetes Research, Vol 2020 (2020)
Journal of Diabetes Research, Vol 2020 (2020)
Background. Several clinical trials have addressed the therapeutic strategy of adding dipeptidyl peptidase 4 (DPP-4) inhibitors to the treatment of type 2 diabetes mellitus (DM) inadequately controlled by insulin therapy. However, there is a high deg
Publikováno v:
Diabetesmetabolic syndrome. 16(4)
Clinical trials indicate the efficacy of add-on therapy using incretin-related drugs to treat type 2 diabetes mellitus (DM) inadequately controlled by insulin. However, heterogeneity exists among these studies. Baseline body mass index (BMI) accounts
Autor:
Yohei, Kawano, Maki, Obana, Masashi, Nagata, Yasunari, Mano, Maho, Katsuyama, Yuichiro, Yamamoto, Ayako, Maeda-Minami, Kenichi, Negishi, Masamichi, Takagi, Shuji, Shimada, Takao, Aoyama
Publikováno v:
European journal of pharmacology. 917
Mirtazapine (MTZ) is a noradrenergic and specific serotonergic antidepressant that has been associated with an increased risk of bleeding. However, there is insufficient evidence confirming this association. We hypothesised that 5-HT
Autor:
Yohei, Kawano, Maho, Katsuyama, Masashi, Nagata, Maki, Obana, Satoshi, Nakamatsu, Ayano, Mori, Namiki, Sakamoto, Yasunari, Mano, Kenichi, Negishi, Shuji, Shimada, Takao, Aoyama
Publikováno v:
Biologicalpharmaceutical bulletin. 44(2)
Mirtazapine (MTZ) is a noradrenergic and specific serotonergic antidepressant. MTZ is reportedly associated with an increased risk of bleeding. However, the underlying mechanism remains unclear. In this study, we investigated the antiplatelet effect
Publikováno v:
Therapeutic Innovation & Regulatory Science. 53:138-145
Drug lag (DL) in Japan has decreased in the last few years as a result of the globalization of drug development in the past decade, and new molecule entities (NMEs) with short DL are on the rise. The purpose of this study was to investigate the influ